Ensign Peak Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $32.7M | Buy |
100,209
+19,730
| +25% | +$6.43M | 0.06% | 240 |
|
|
2025
Q1 | $21.7M | Buy |
80,479
+4,015
| +5% | +$1.08M | 0.04% | 289 |
|
|
2024
Q4 | $18M | Sell |
76,464
-4,104
| -5% | -$966K | 0.03% | 337 |
|
|
2024
Q3 | $22.2M | Buy |
80,568
+7,095
| +10% | +$1.95M | 0.04% | 308 |
|
|
2024
Q2 | $17.9M | Sell |
73,473
-8,297
| -10% | -$2.02M | 0.03% | 330 |
|
|
2024
Q1 | $12.2M | Sell |
81,770
-5,827
| -7% | -$871K | 0.02% | 416 |
|
|
2023
Q4 | $16.8M | Buy |
87,597
+28,373
| +48% | +$5.43M | 0.03% | 327 |
|
|
2023
Q3 | $10.5M | Buy |
59,224
+11,904
| +25% | +$2.11M | 0.02% | 380 |
|
|
2023
Q2 | $8.99M | Buy |
47,320
+7,745
| +20% | +$1.47M | 0.02% | 444 |
|
|
2023
Q1 | $7.93M | Buy |
39,575
+2,482
| +7% | +$497K | 0.02% | 456 |
|
|
2022
Q4 | $8.82M | Buy |
37,093
+1,563
| +4% | +$371K | 0.02% | 444 |
|
|
2022
Q3 | $7.11M | Sell |
35,530
-1,335
| -4% | -$267K | 0.02% | 438 |
|
|
2022
Q2 | $5.38M | Buy |
36,865
+435
| +1% | +$63.4K | 0.01% | 515 |
|
|
2022
Q1 | $5.95M | Sell |
36,430
-4,330
| -11% | -$707K | 0.01% | 544 |
|
|
2021
Q4 | $6.91M | Sell |
40,760
-127,839
| -76% | -$21.7M | 0.01% | 570 |
|
|
2021
Q3 | $31.8M | Sell |
168,599
-4,144
| -2% | -$782K | 0.07% | 234 |
|
|
2021
Q2 | $29.3M | Buy |
172,743
+4,942
| +3% | +$838K | 0.06% | 259 |
|
|
2021
Q1 | $23.7M | Buy |
167,801
+57,463
| +52% | +$8.11M | 0.05% | 283 |
|
|
2020
Q4 | $14.3M | Sell |
110,338
-2,870
| -3% | -$373K | 0.03% | 367 |
|
|
2020
Q3 | $16.5M | Buy |
113,208
+37,241
| +49% | +$5.42M | 0.04% | 342 |
|
|
2020
Q2 | $11.3M | Buy |
75,967
+36,010
| +90% | +$5.33M | 0.03% | 397 |
|
|
2020
Q1 | $4.35M | Buy |
39,957
+35,266
| +752% | +$3.84M | 0.01% | 543 |
|
|
2019
Q4 | $540K | Buy |
+4,691
| New | +$540K | ﹤0.01% | 1496 |
|